A Phase 2 interventional study of LCZ696 and Valsartan in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 182 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-08-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.
Among the 227 studies in Hypertension by Novartis, this one is the 16th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2007, is one of 29 in phase 2, and was the 127th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–99
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Japan, Singapore
Ages 18+
By country, each count listing its studies:
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 109 · Phase 4 67
First in 1989; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,334 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 309 across the 222 interventional studies, 813 across the 4 observational. Of the 219 that completed or were terminated, 88 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Hypertension by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07465666Novartis PharmaceuticalsA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 227 studies in Hypertension by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
Drug: LCZ696 · Drug: Placebo
Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
Drug: LCZ696 · Drug: Placebo
Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
Drug: LCZ696 · Drug: Placebo
Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
Drug: Valsartan · Drug: Placebo
Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
Drug: Valsartan · Drug: Placebo
Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
Drug: Valsartan · Drug: Placebo
Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
Drug: AHU377 · Drug: Placebo
Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
Drug: Placebo
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.
Time frame: baseline, week 8
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Sitting BP measurements were performed at screening through the end of the study at every study visit.
Time frame: baseline, week 8
Change From Baseline in 24-hour Mean Ambulatory DBP (maDBP) and maSBP
Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8.
Time frame: baseline, 8 weeks
Change From Baseline in Daytime maDBP and maSBP
Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the avergae of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm.
Time frame: baseline, 8 weeks
Change From Baseline in Nighttime maDBP and maSBP
Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am.
Time frame: baseline, 8 weeks
Percentage of Participants Who Achieved a Successful Response in msDBP
Successful response in msDBP is defined as msDBP \<90 mmHg or a reduction ≥ 10 mmHg from baseline.
Time frame: 8 weeks
Percentage of Participants Who Achieved a Successful Response in msSBP
Successful response in msSBP is defined as msSBP \<140 mmHg or a reduction ≥ 20 mmHg from baseline.
Time frame: 8 weeks
Percentage of Participants Who Achieved Successful Control in msDBP
Successful control in msDBP is defined as msDBP \<90 mmHg.
Time frame: 8 weeks
Percentage of Participants Who Achieved Successful Control in msSBP
Successful control in msSBP is defined as \<140 mmHg.
Time frame: 8 weeks
The study comprised 3 periods: a 4-week washout and placebo run-in period (pre-randomization), an 8-week randomized, double-blind monotherapy period, and 1-week randomized, placebo-controlled withdrawal period. In the randomized withdrawal, participants were either randomized to placebo or continued their original assigned treatment.
| Milestone | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 156 | 169 | 172 | 163 | 166 | 164 | 165 | 173 |
| Intent-to-treat population | 154 | 168 | 170 | 163 | 163 | 163 | 164 | 172 |
| Ambulatory blood pressure monitoring | 48 | 61 | 53 | 55 | 49 | 54 | 50 | 57 |
| Completed | 149 | 158 | 162 | 147 | 149 | 151 | 151 | 148 |
| Not completed | 7 | 11 | 10 | 16 | 17 | 13 | 14 | 25 |
| Withdrew: Protocol deviation | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
| Withdrew: Administrative problems | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 | 3 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 6 | 4 | 5 | 6 | 6 | 4 | 9 |
| Withdrew: Lack of efficacy | 1 | 0 | 2 | 3 | 5 | 1 | 3 | 8 |
| Withdrew: Abnormal test procedure results | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 1 |
| Withdrew: Abnormal laboratory values | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 3 | 1 | 2 | 1 | 0 | 5 | 4 |
Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.
| mmHg | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) | -9.97 ± 0.73 | -12.92 ± 0.70 | -13.63 ± 0.70 | -9.14 ± 0.72 | -9.95 ± 0.71 | -10.93 ± 0.71 | -9.76 ± 0.71 | -6.78 ± 0.69 |
Sitting BP measurements were performed at screening through the end of the study at every study visit.
| mmHg | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) | -13.75 ± 1.15 | -18.70 ± 1.10 | -20.17 ± 1.10 | -12.44 ± 1.12 | -13.42 ± 1.12 | -14.16 ± 1.12 | -11.93 ± 1.11 | -7.72 ± 1.09 |
Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8.
| mmHg | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| maDBP | -3.80 ± 0.72 | -6.78 ± 0.64 | -8.32 ± 0.71 | -4.56 ± 0.67 | -6.25 ± 0.70 | -7.13 ± 0.67 | -3.67 ± 0.70 | -1.33 ± 0.67 |
| maSBP | -7.80 ± 1.04 | -11.50 ± 0.93 | -14.56 ± 1.03 | -7.29 ± 0.96 | -8.27 ± 1.00 | -9.42 ± 0.97 | -5.18 ± 1.02 | -2.90 ± 0.96 |
Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the avergae of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm.
| mmHg | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| maDBP | -4.05 ± 1.23 | -6.91 ± 1.12 | -7.80 ± 1.19 | -4.78 ± 1.17 | -7.40 ± 1.23 | -7.47 ± 1.17 | -3.18 ± 1.22 | -1.53 ± 1.14 |
| maSBP | -7.96 ± 1.73 | -11.76 ± 1.58 | -14.20 ± 1.67 | -7.59 ± 1.65 | -9.54 ± 1.73 | -9.90 ± 1.66 | -4.49 ± 1.72 | -3.40 ± 1.61 |
Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am.
| mmHg | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| maDBP | -2.87 ± 1.25 | -7.73 ± 1.13 | -6.93 ± 1.23 | -4.04 ± 1.17 | -4.18 ± 1.24 | -6.17 ± 1.18 | -3.31 ± 1.24 | -1.01 ± 1.16 |
| maSBP | -6.40 ± 1.77 | -11.85 ± 1.60 | -12.04 ± 1.73 | -6.43 ± 1.66 | -5.82 ± 1.74 | -7.51 ± 1.67 | -3.99 ± 1.75 | -2.09 ± 1.63 |
Successful response in msDBP is defined as msDBP \<90 mmHg or a reduction ≥ 10 mmHg from baseline.
| Percentage of participants | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Successful Response in msDBP | 53.90 | 69.64 | 74.12 | 51.53 | 55.83 | 63.19 | 54.27 | 39.53 |
Successful response in msSBP is defined as msSBP \<140 mmHg or a reduction ≥ 20 mmHg from baseline.
| Percentage of participants | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Successful Response in msSBP | 55.84 | 63.69 | 72.35 | 51.53 | 51.53 | 57.06 | 46.34 | 37.79 |
Successful control in msDBP is defined as msDBP \<90 mmHg.
| Percentage of participants | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Successful Control in msDBP | 47.40 | 60.12 | 65.88 | 45.40 | 47.85 | 56.44 | 46.95 | 38.37 |
Successful control in msSBP is defined as \<140 mmHg.
| Percentage of participants | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Successful Control in msSBP | 47.40 | 56.55 | 62.94 | 45.40 | 42.33 | 53.37 | 37.20 | 31.98 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LCZ696 100 mg | — | 1/156 (0.6%) | 4/156 (2.6%) |
| LCZ696 200 mg | — | 0/169 (0%) | 4/169 (2.4%) |
| LCZ696 400 mg | — | 1/172 (0.6%) | 4/172 (2.3%) |
| Valsartan 80 mg | — | 1/163 (0.6%) | 5/163 (3.1%) |
| Valsartan 160 mg | — | 0/166 (0%) | 4/166 (2.4%) |
| Valsartan 320 mg | — | 0/164 (0%) | 3/164 (1.8%) |
| AHU377 200 mg | — | 0/165 (0%) | 5/165 (3%) |
| Placebo | — | 0/173 (0%) | 13/173 (7.5%) |
| Event | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 1/156 | 0/169 | 0/172 | 0/163 | 0/166 | 0/164 | 0/165 | 0/173 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/156 | 0/169 | 0/172 | 0/163 | 0/166 | 0/164 | 0/165 | 0/173 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 0/169 | 0/172 | 1/163 | 0/166 | 0/164 | 0/165 | 0/173 |
| Back painMusculoskeletal and connective tissue disorders | 0/156 | 0/169 | 1/172 | 0/163 | 0/166 | 0/164 | 0/165 | 0/173 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/156 | 0/169 | 1/172 | 0/163 | 0/166 | 0/164 | 0/165 | 0/173 |
| Event | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/156 | 4/169 | 4/172 | 5/163 | 4/166 | 3/164 | 5/165 | 13/173 |
| Age, Continuous(years) | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 53 ± 10.4 | 54 ± 9.7 | 52 ± 10.9 | 53 ± 9.6 | 53 ± 9.7 | 53 ± 10.1 | 53 ± 10.7 | 54 ± 10.6 | 53 ± 10.2 |
| Sex: Female, Male(Participants) | LCZ696 100 mg | LCZ696 200 mg | LCZ696 400 mg | Valsartan 80 mg | Valsartan 160 mg | Valsartan 320 mg | AHU377 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 61 | 77 | 75 | 68 | 68 | 65 | 75 | 79 | 568 |
| Male | 95 | 92 | 97 | 95 | 98 | 99 | 90 | 94 | 760 |
Showing the first 100 of 182 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 7 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sacubitril